BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

U.S. Department Of Health And Human Services And Centers For Disease Control And Prevention Announce Intention to Increase Proportion Of Relenza In Avian Flu Pandemic Stockpile


7/24/2006 12:10:51 PM

MELBOURNE, Australia and WASHINGTON, July 24 /PRNewswire/ -- The United States Department of Health and Human Services (HHS) has announced a contract award with GlaxoSmithKline (GSK) to assist states to increase their stockpiles of the influenza antiviral drug Relenza(R) (zanamivir). This announcement followed a report released by the Department of Human Health Services, Centers for Disease Control and Prevention on June 29, which outlined HHS plans to increase the proportion of Relenza in the US stockpile to 20 percent of the targeted total of 81 million courses.

The HHS attributed the increase to the effectiveness of Relenza against H5N1 stranis resistant to Tamiflu(R) (oseltamivir phosphate). Biota receives royalties from the sale of Relenza, which is marketed by GSK. A full copy of the HHS news release of 20 July 2006, is available at http://www.hhs.gov/news/press/2006pres/20060720.html.

About Biota

Biota is a world-leading antiviral drug development company based in Melbourne, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor drug, zanamivir, subsequently marketed by GSK as Relenza. Relenza is currently being stockpiled by a number of national governments for defense against avian influenza. Biota receives royalties from sales of Relenza.

Recent Biota research breakthroughs have included a series of candidate drugs aimed at Respiratory Syncytial Virus (subsequently licensed to MedImmune Inc.) and Human Rhinovirus. Biota is also engaged in early stage research targeting hepatitis C virus infection. In addition, Biota has key partnerships with Sankyo; for the development of second generation flu antivirals (called LANI or Long Acting Neuraminidase Inhibitors) and with Thermo Electron; Biota developed the FLU OIA(R) influenza diagnostics, currently marketed in the US.

(TM) Relenza is a registered trademark of the GlaxoSmithKline group of companies.

(R) FLU OIA & FLU OIA A/B are registered trademarks of Thermo Electron Corporation.

*Further information is available at http://www.biota.com.au.

Biota

CONTACT: David Sheon of SciWords, LLC, +1-202-518-6321, for Biota



Read at BioSpace.com

   
Bird Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES